Remedy Plan Therapeutics
Dexter joins the Remedy Plan team with more than three years of experience in the pharmaceutical industry and a strong background in medicinal chemistry. He has successfully optimized and developed clinical drug candidates in the area of small molecule antivirals targeting hepatitis B and SARS-CoV-2. He received his Ph.D. in organic chemistry from Purdue University and carried out postdoctoral work at the Warren Center for Neuroscience Drug Discovery at Vanderbilt University.
This person is not in any offices
Remedy Plan Therapeutics
Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.